Researchers at Simon Fraser University are studying the genes of superbugs to aid the development of new and effective treatments for drug-resistant bacterial infections.  Superbugs are characterized as infection-causing bacteria resistant to treatment with antibiotics. “Antimicrobial resistance occurs when the disease-causing bacteria has ways to overcome the antibiotics that we use in treatment for infections,” says assistant professor Amy Lee,…
Read More

Discovering the Likely Cause of Manic Symptoms in Bipolar Disorders

Researchers have found a link between the reduced activity of a mood-regulating neurotransmitter in the brain and bipolar mania. In a breakthrough study, researchers have identified a potential root cause of acute manic symptoms among people with bipolar disorder. Characterized by periods of extreme highs followed by long-lasting depression, bipolar disorder can have harmful effects on patients and their loved…
Read More
New University of British Columbia research is challenging a longstanding assumption that a baby’s gut microbiome is primarily shaped by their mother’s vaginal microbiome, while shedding new light on the factors that do influence its development. When babies are born, their gut is a nearly sterile environment. But that quickly changes as the infant’s digestive tract becomes home to trillions…
Read More
Gandeeva Therapeutics, Inc., a precision medicine company focused on designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the initiation of a research collaboration with Moderna Inc. (NASDAQ: MRNA) to explore applications of Gandeeva’s differentiated technology platform for a Moderna program. “We are excited to begin working with Moderna on a specific application…
Read More
A Vancouver-based therapeutics company has begun a second Phase II trial of its novel long lasting non-opioid pain medication, with a specific focus on treating Chronic Scrotal Pain (CSP), a debilitating condition estimated to affect 1% of the male population. Sustained Therapeutics’ first sustained release drug candidate, ST-01, is designed to slowly release over about 28 days from a single…
Read More
Few people have made bigger contributions to the Canadian regenerative medicine ecosystem than Dr. Peter Zandstra. He is co-founder of two companies advancing cutting-edge biotechnologies for therapeutic use (Notch Therapeutics and ExCellThera, both of which are developing technologies set to transform the lives of patients) and he’s the founding Director of the University of British Columbia’s School of Biomedical Engineering (SBME), a…
Read More
Autoimmunity may be the driver of long COVID, according to a new study published in the European Respiratory Journal. Roughly 10 to 20 per cent of people who recover from COVID-19 experience lasting symptoms after their initial infection, including fatigue, cough, shortness of breath, and cognitive impairment.
Read More

Honing In on Precision Treatments for Endometriosis

Often called an invisible disease, endometriosis can have a significant negative impact on a person’s physical and mental health. A recent study suggests the condition affects around seven per cent of Canadians of reproductive age who have a uterus, though the actual number may be higher. Many individuals seeking diagnosis and treatment experience a diagnostic delay of more than five years. There is…
Read More
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s…
Read More